A Phase 2 interventional study of Acetaminophen and Placebo in Pain, Postoperative and Dental Pain, sponsored by Nevakar, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-29.
Sponsored by Nevakar, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.
Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 47th largest by enrollment, is one of 9 that started in 2019, is one of 9 in phase 2, and was the 76th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
University of Puerto Rico · Sites in Puerto Rico
Ages 21–65
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Rothman Institute Orthopaedics · Sites in United States
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 17 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 23 · Phase 4 53
First in 2002; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 118 interventional studies. Of the 88 that completed or were terminated, 41 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 118 have an industry lead sponsor. The 10 most frequent:
Nevakar, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Nevakar, Inc. has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing acetaminophen in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571252University of Puerto RicoImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | 2026-12 |
| NCT06997016Baylor Research InstituteEnhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients | 2027-06 |
| NCT03105518Brigham and Women's HospitalPredictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 2027-06-30 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07720791Konya City HospitalAcetaminophen vs Placebo for Postoperative Analgesia After Abdominal Surgery | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 118 studies testing acetaminophen in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the safety, tolerability, analgesic, efficacy and pharmacokinetics of high dose acetaminophen relative to placebo and low dose acetaminophen relative to placebo over a 24 hour period in patient experiencing moderate to severe pain following the surgical removal of third molar.
This will be a randomized, double-blind, single-site, placebo-controlled, parallel-group study to assess similarities in safety, tolerability, efficacy, and pharmacokinetics of high dose acetaminophen given relative to placebo, and low dose acetaminophen given relative to placebo over a 24-hour period in patients experiencing moderate to severe postsurgical pain within 7 hours following surgical removal of 2 or more molars
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who are scheduled to undergo the surgical removal of up to 4 third molars of which at least two have to be mandibular molars with a difficulty rating of 4 or 5 and meeting the following criteria:
Exclusion Criteria:
Patients with liver function tests (, AST) that are above the normal reference range.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High Dose Acetaminophen Post Op
Drug: Acetaminophen
Low Dose Acetaminophen Post Op
Drug: Acetaminophen
Placebo Post Op
Other: Placebo
Acetaminophen is an analgesic and antipyretic
Also known as: APAP
Saline
Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale
Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Time weighted sum of pain intensity difference from 0 to 24 hours was reported. Pain Intensity (PI-NPRS) was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min). SPID24 was include all nominal timepoints from T0 to T24.25 hours. SPID is calculated as Σ\[T(i) -T(i-1)\] x \[(PID(i-1) + PID(i))/2\], where T(0)=0, T(i) is the scheduled time, and PID(i) is the pain intensity difference (PID) score at time i. Pain intensity differences were calculated with respect to Baseline. A baseline assessment is defined as the last non-missing result prior to administration of the first dose of study medication.
Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours
Sum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale.
Pain Relief Rating (PR) was scored on a 5-point scale (0=no-, 1=a little-, 2=some-, 3=a lot of-, and 4=complete- PR). PR was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours. TOTPAR24 is calculated as Sum (\[T(i) - T(i-1)\] x (PR(i-1) + PR(i)) / 2), where T(0)=0, T(i) is the actual time, and PR(i) is the pain relief score at time i. and calculated as Σ\[T(i) -T(i-1)\] x \[(PR(i-1) + PR(i))/2\], where T(0)=0, T(i) is the scheduled time, and PR(i) is the pain relief (PR) score at time i.
Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours
Time to Perceptible Pain Relief Confirmed (FPR-C) After Dose 1 Administration Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups
Upon initiation of the infusion of Dose 1, the participants were given stopwatch #1 and asked to press the stopwatch when they first perceived any pain relief (first perceptible pain relief \[FPR\]) ; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours
Time frame: 0 to 24 Hours
Time to Meaningful Perceptible Relief (MPR) Measure Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups
Upon initiation of the infusion of Dose 1, the participants were given a second stopwatch and asked to press the stopwatch if and when they feel any meaningful perceptible relief; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and was prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours.
Time frame: 0 to 24 Hours
Patient Global Evaluation of the Study Medication
Patients Global Evaluation was assessed on a scale of 0 (Poor), 1 (Fair), 2 (Good), 3 (Very Good) and 4 (Excellent) at 24.25 hours post-dose 1 or at participant withdrawal (if applicable), whichever occurred first. Least squares mean of the score are reported.
Time frame: 0 to 24 Hours
Pain Intensity Difference Rating (PID) at Different Timepoints After Dose 1 Administration
Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to Baseline at each time point after Dose 1 administration. A baseline assessment was defined as the last non-missing result prior to administration of the first dose of study medication
Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 hours (± 10 min)
Pain Intensity Rating at Different Timepoints After Dose 1 Administration
Pain intensity is reported using the 11-point Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain).
Time frame: 0 to 24 hours
Pain Relief (PR) Ratings at Each Observation Time After Dose 1 Administration
Pain Relief is reported on a 5-Point Categorical Pain Relief Assessment scale: 0 = No Pain Relief, 1 = A Little Pain Relief, 2 = Some Pain Relief, 3 = A Lot of Pain Relief, 4 = Complete Pain Relief.
Time frame: 0 to 24 hours
Time to Treatment Failure
Time to treatment failure is defined as time to first dose of rescue medication after Dose 1 or withdrawal from the study for any reason. If a participant does not take rescue medication or withdraw from the study prior to 24 hours, the participant was censored at 24 hours
Time frame: 0 to 24 Hours
Mean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure)
Change from Baseline in systolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Systolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min).
Time frame: 0 to 24 hours
Mean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure)
Change from Baseline in diastolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Diastolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
Time frame: 0 to 24 hours
Mean Change From Baseline to 24 Hours in Vital Signs (Temperature)
Change from Baseline in temperature is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Temperature is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
Time frame: 0 to 24 hours
Mean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate)
Change from Baseline in pulse rate is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Pulse rate is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
Time frame: 0 to 24 hours
Mean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate)
Change from Baseline in respiratory rate was the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Respiratory rate was obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
Time frame: 0 to 24 hours
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h)
The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The values for pharmacokinetic (PK) evaluable population-excluding participants with positive pre-dose concentrations have been populated. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.
Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.
Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Half-life
The half-life (t 1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Maximum Observed Plasma Concentration (Cmax)
The Plasma Concentration (Cmax) is defined as maximum observed concentration
Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Participants were recruited from April 2019 till July 2019 from the site
| Milestone | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Started | 44 | 44 | 22 |
| Completed | 43 | 44 | 21 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Time weighted sum of pain intensity difference from 0 to 24 hours was reported. Pain Intensity (PI-NPRS) was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min). SPID24 was include all nominal timepoints from T0 to T24.25 hours. SPID is calculated as Σ\[T(i) -T(i-1)\] x \[(PID(i-1) + PID(i))/2\], where T(0)=0, T(i) is the scheduled time, and PID(i) is the pain intensity difference (PID) score at time i. Pain intensity differences were calculated with respect to Baseline. A baseline assessment is defined as the last non-missing result prior to administration of the first dose of study medication.
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale | -96.80 ± 6.369 | -100.69 ± 6.333 | -74.96 ± 9.055 |
Pain Relief Rating (PR) was scored on a 5-point scale (0=no-, 1=a little-, 2=some-, 3=a lot of-, and 4=complete- PR). PR was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours. TOTPAR24 is calculated as Sum (\[T(i) - T(i-1)\] x (PR(i-1) + PR(i)) / 2), where T(0)=0, T(i) is the actual time, and PR(i) is the pain relief score at time i. and calculated as Σ\[T(i) -T(i-1)\] x \[(PR(i-1) + PR(i))/2\], where T(0)=0, T(i) is the scheduled time, and PR(i) is the pain relief (PR) score at time i.
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Sum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale. | 55.82 ± 3.024 | 55.24 ± 3.007 | 43.11 ± 4.300 |
Upon initiation of the infusion of Dose 1, the participants were given stopwatch #1 and asked to press the stopwatch when they first perceived any pain relief (first perceptible pain relief \[FPR\]) ; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours
| hours | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Median time to FPR-C (hours)- for moderate baseline categorical pain intensity score | 0.215 (0.080 to 1.000) | 0.160 (0.030 to 0.430) | 0.595 (0.060 to 24.00) |
| Median time to FPR-C (hours)- for severe baseline categorical pain intensity score | 0.160 (0.030 to 24.00) | 0.220 (0.060 to 24.00) | 0.890 (0.040 to 24.00) |
Upon initiation of the infusion of Dose 1, the participants were given a second stopwatch and asked to press the stopwatch if and when they feel any meaningful perceptible relief; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and was prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours.
| hours | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Median time to MPR (hours)- for moderate baseline categorical pain intensity score | 0.660 (0.250 to 24.00) | 0.310 (0.110 to 24.00) | NA (NA to NA) |
| Median time to MPR (hours)- for severe baseline categorical pain intensity score | 0.680 (0.120 to 24.00) | 0.870 (0.150 to 24.00) | NA (NA to NA) |
Patients Global Evaluation was assessed on a scale of 0 (Poor), 1 (Fair), 2 (Good), 3 (Very Good) and 4 (Excellent) at 24.25 hours post-dose 1 or at participant withdrawal (if applicable), whichever occurred first. Least squares mean of the score are reported.
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Patient Global Evaluation of the Study Medication | 2.8 ± 0.16 | 2.7 ± 0.15 | 2.3 ± 0.22 |
Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to Baseline at each time point after Dose 1 administration. A baseline assessment was defined as the last non-missing result prior to administration of the first dose of study medication
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| 0.5 | -2.5 ± 1.65 | -3.1 ± 2.01 | -0.7 ± 1.28 |
| 0.75 | -3.3 ± 1.88 | -3.5 ± 2.10 | -0.8 ± 1.40 |
| 1 | -3.7 ± 1.89 | -3.8 ± 2.12 | -0.8 ± 1.44 |
| 1.25 | -3.9 ± 2.02 | -4.0 ± 2.29 | -0.7 ± 1.52 |
| 1.75 | -3.9 ± 1.97 | -3.7 ± 2.45 | -0.7 ± 1.59 |
| 2.25 | -3.8 ± 2.16 | -3.6 ± 2.44 | -0.7 ± 1.67 |
| 3.25 | -3.4 ± 2.32 | -3.0 ± 2.39 | -0.9 ± 1.95 |
| 4.25 | -3.4 ± 2.40 | -2.9 ± 2.32 | -0.9 ± 1.97 |
| 5.25 | -3.3 ± 2.48 | -2.8 ± 2.39 | -2.4 ± 2.59 |
| 6.25 | -3.2 ± 2.48 | -3.5 ± 2.49 | -3.7 ± 2.32 |
| 7.25 | -3.0 ± 2.61 | -4.1 ± 2.34 | -4.2 ± 1.99 |
| 8.25 | -3.8 ± 2.72 | -4.4 ± 2.29 | -3.7 ± 2.36 |
| 9.25 | -4.5 ± 2.89 | -4.7 ± 2.18 | -3.6 ± 2.26 |
| 10.25 | -4.6 ± 2.71 | -5.0 ± 1.98 | -3.4 ± 2.22 |
| 11.25 | -4.7 ± 2.44 | -4.5 ± 1.99 | -3.3 ± 2.28 |
| 12.25 | -4.9 ± 1.85 | -4.5 ± 2.31 | -2.7 ± 2.27 |
| 14.25 | -3.7 ± 2.13 | -5.0 ± 2.42 | -2.9 ± 1.97 |
| 16.25 | -3.5 ± 2.29 | -4.4 ± 2.08 | -2.9 ± 1.97 |
| 18.25 | -4.4 ± 2.34 | -4.5 ± 2.27 | -3.5 ± 1.97 |
| 20.25 | -4.7 ± 2.04 | -4.9 ± 2.37 | -3.6 ± 2.24 |
| 22.25 | -4.7 ± 2.25 | -5.0 ± 2.35 | -3.9 ± 2.19 |
| 24.25 | -4.6 ± 2.29 | -5.1 ± 2.42 | -4.3 ± 1.86 |
Pain intensity is reported using the 11-point Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain).
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| 0.5 | 4.8 ± 1.83 | 4.4 ± 1.97 | 6.1 ± 1.42 |
| 0.75 | 4.0 ± 2.12 | 4.0 ± 1.98 | 6.0 ± 1.70 |
| 1 | 3.6 ± 1.98 | 3.7 ± 2.01 | 6.0 ± 1.68 |
| 1.25 | 3.4 ± 2.16 | 3.5 ± 2.14 | 6.2 ± 1.89 |
| 1.75 | 3.5 ± 2.24 | 3.8 ± 2.33 | 6.2 ± 1.94 |
| 2.25 | 3.6 ± 2.40 | 3.9 ± 2.39 | 6.2 ± 1.97 |
| 3.25 | 3.9 ± 2.53 | 4.5 ± 2.48 | 6.0 ± 2.17 |
| 4.25 | 4.0 ± 2.58 | 4.6 ± 2.33 | 6.0 ± 2.21 |
| 5.25 | 4.0 ± 2.48 | 4.7 ± 2.44 | 4.5 ± 2.56 |
| 6.25 | 4.2 ± 2.52 | 4.0 ± 2.59 | 3.2 ± 2.11 |
| 7.25 | 4.3 ± 2.46 | 3.4 ± 2.22 | 2.7 ± 1.86 |
| 8.25 | 3.5 ± 2.58 | 3.1 ± 2.20 | 3.2 ± 2.30 |
| 9.25 | 2.9 ± 2.71 | 2.8 ± 1.95 | 3.3 ± 2.25 |
| 10.25 | 2.8 ± 2.48 | 2.5 ± 1.68 | 3.5 ± 2.15 |
| 11.25 | 2.7 ± 2.27 | 3.0 ± 1.66 | 3.5 ± 2.24 |
| 12.25 | 2.5 ± 1.83 | 3.0 ± 2.09 | 4.1 ± 2.32 |
| 14.25 | 3.6 ± 2.29 | 2.5 ± 2.11 | 4.0 ± 2.08 |
| 16.25 | 3.8 ± 2.55 | 3.1 ± 2.01 | 4.0 ± 2.21 |
| 18.25 | 2.9 ± 2.58 | 3.0 ± 2.23 | 3.4 ± 1.99 |
| 20.25 | 2.7 ± 2.28 | 2.6 ± 2.14 | 3.2 ± 2.22 |
| 22.25 | 2.6 ± 2.58 | 2.5 ± 1.96 | 3.0 ± 2.16 |
| 24.25 | 2.8 ± 2.38 | 2.4 ± 2.06 | 2.61 ± 1.71 |
Pain Relief is reported on a 5-Point Categorical Pain Relief Assessment scale: 0 = No Pain Relief, 1 = A Little Pain Relief, 2 = Some Pain Relief, 3 = A Lot of Pain Relief, 4 = Complete Pain Relief.
| score on a scale | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| 0.5 | 1.7 ± 0.95 | 1.8 ± 0.94 | 0.6 ± 0.85 |
| 0.75 | 2.0 ± 1.02 | 2.0 ± 0.98 | 0.6 ± 0.85 |
| 1 | 2.1 ± 0.93 | 2.2 ± 0.96 | 0.6 ± 0.85 |
| 1.25 | 2.3 ± 0.97 | 2.2 ± 0.99 | 0.6 ± 0.85 |
| 1.75 | 2.3 ± 0.97 | 2.0 ± 1.07 | 0.6 ± 0.90 |
| 2.25 | 2.2 ± 1.09 | 2.0 ± 1.05 | 0.6 ± 0.90 |
| 3.25 | 2.0 ± 1.18 | 1.7 ± 1.12 | 0.8 ± 1.15 |
| 4.25 | 2.0 ± 1.21 | 1.6 ± 1.12 | 0.7 ± 1.08 |
| 5.25 | 1.9 ± 1.20 | 1.5 ± 1.21 | 1.5 ± 1.44 |
| 6.25 | 1.9 ± 1.23 | 1.9 ± 1.15 | 2.1 ± 1.25 |
| 7.25 | 1.8 ± 1.21 | 2.2 ± 1.03 | 2.5 ± 1.10 |
| 8.25 | 2.2 ± 1.15 | 2.4 ± 1.06 | 2.2 ± 1.27 |
| 9.25 | 2.6 ± 1.22 | 2.5 ± 0.93 | 2.1 ± 1.19 |
| 10.25 | 2.6 ± 1.10 | 2.7 ± 0.80 | 2.0 ± 1.20 |
| 11.25 | 2.7 ± 0.97 | 2.5 ± 0.87 | 2.0 ± 1.31 |
| 12.25 | 2.7 ± 0.83 | 2.4 ± 1.04 | 1.6 ± 1.33 |
| 14.25 | 2.1 ± 1.00 | 2.6 ± 1.04 | 1.8 ± 1.11 |
| 16.25 | 2.1 ± 1.14 | 2.3 ± 1.06 | 1.8 ± 1.14 |
| 18.25 | 2.5 ± 1.10 | 2.4 ± 1.02 | 2.1 ± 1.17 |
| 20.25 | 2.7 ± 1.00 | 2.6 ± 0.95 | 2.2 ± 1.18 |
| 22.25 | 2.7 ± 1.11 | 2.6 ± 0.94 | 2.3 ± 1.09 |
| 24.25 | 2.5 ± 1.12 | 2.7 ± 0.99 | 2.5 ± 0.91 |
Time to treatment failure is defined as time to first dose of rescue medication after Dose 1 or withdrawal from the study for any reason. If a participant does not take rescue medication or withdraw from the study prior to 24 hours, the participant was censored at 24 hours
| hours | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Median time to treatment failure- for moderate baseline categorical pain intensity score | NA (NA to NA) | NA (NA to NA) | 3.680 (1.100 to 24.00) |
| Median time to treatment failure for severe baseline categorical pain intensity score | NA (NA to NA) | NA (NA to NA) | 1.335 (1.030 to 24.00) |
Change from Baseline in systolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Systolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min).
| mm Hg | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Mean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure) | 1.6 ± 10.78 | 1.0 ± 11.39 | 9.2 ± 10.99 |
Change from Baseline in diastolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Diastolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
| mm Hg | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Mean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure) | -0.2 ± 8.82 | 2.3 ± 9.56 | 5.2 ± 11.08 |
Change from Baseline in temperature is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Temperature is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
| degrees Celsius | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Mean Change From Baseline to 24 Hours in Vital Signs (Temperature) | 0.12 ± 0.336 | 0.21 ± 0.275 | 0.06 ± 0.347 |
Change from Baseline in pulse rate is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Pulse rate is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
| beats/minute | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Mean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate) | 5.0 ± 11.85 | 4.2 ± 11.58 | 5.7 ± 11.17 |
Change from Baseline in respiratory rate was the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Respiratory rate was obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)
| breaths/minute | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| Mean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate) | 0.3 ± 3.39 | -0.6 ± 4.12 | -1.3 ± 3.68 |
The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The values for pharmacokinetic (PK) evaluable population-excluding participants with positive pre-dose concentrations have been populated. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.
| microgram*hour/milliliter | High Dose APAP | Low Dose APAP |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h) | 236326.3081 ± 1.06026 | 231104.0073 ± 1.05427 |
The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.
| hour*nanogram per milliliter | High Dose APAP | Low Dose APAP |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) | 75925.2553 ± 22.405 | 55018.1382 ± 27.089 |
The half-life (t 1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
| hours | High Dose APAP | Low Dose APAP |
|---|---|---|
| Half-life | 2.565 ± 0.5774 | 2.360 ± 0.4134 |
The Plasma Concentration (Cmax) is defined as maximum observed concentration
| nanogram per milliliter (ng/ml) | High Dose APAP | Low Dose APAP |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 39531.4 ± 26 | 28495.6 ± 30 |
Collected over Up to 7 days (± 2 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose APAP | 0/44 (0%) | 0/44 (0%) | 9/44 (20.5%) |
| Low Dose APAP | 0/44 (0%) | 0/44 (0%) | 13/44 (29.5%) |
| Placebo | 0/22 (0%) | 0/22 (0%) | 7/22 (31.8%) |
| Event | High Dose APAP | Low Dose APAP | Placebo |
|---|---|---|---|
| HyperbilirubinaemiaHepatobiliary disorders | 7/44 | 8/44 | 6/22 |
| NauseaGastrointestinal disorders | 1/44 | 1/44 | 1/22 |
| DizzinessNervous system disorders | 0/44 | 0/44 | 1/22 |
| HeadacheNervous system disorders | 0/44 | 0/44 | 1/22 |
| TachycardiaCardiac disorders | 0/44 | 1/44 | 0/22 |
| Hypoaesthesia oralGastrointestinal disorders | 0/44 | 1/44 | 0/22 |
| Infusion site extravasationGeneral disorders | 1/44 | 0/44 | 0/22 |
| Infusion site haematomaGeneral disorders | 1/44 | 0/44 | 0/22 |
| PyrexiaGeneral disorders | 1/44 | 1/44 | 0/22 |
| Postoperative wound infectionInfections and infestations | 0/44 | 1/44 | 0/22 |
Baseline analysis population was the Safety Population that included all randomized participants who received the study medication.
| Age, Continuous(years) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| Mean | 18.7 ± 2.06 | 18.8 ± 2.31 | 19.3 ± 2.42 | 18.9 ± 2.23 |
| Sex: Female, Male(Participants) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| Female | 25 | 22 | 11 | 58 |
| Male | 19 | 22 | 11 | 52 |
| Race/Ethnicity, Customized(Participants) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| Race-Asian | 1 | 0 | 0 | 1 |
| Race-White | 39 | 39 | 22 | 100 |
| Race-Others | 2 | 4 | 0 | 6 |
| Race-Black or African American | 1 | 0 | 0 | 1 |
| Race- Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Ethnicity-Hispanic or Latino | 9 | 8 | 1 | 18 |
| Ethinicity-Not Hispanic or Latino | 35 | 36 | 21 | 92 |
| Body Mass Index(kg/m^2) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| Mean | 24.45 ± 4.124 | 24.33 ± 3.762 | 25.49 ± 4.869 | 24.61 ± 4.130 |
| Categorical pain intensity score(Participants) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| None (0) | 0 | 0 | 0 | 0 |
| Mild (1) | 0 | 0 | 0 | 0 |
| Moderate (2) | 14 | 11 | 10 | 35 |
| Severe (3) | 30 | 33 | 12 | 75 |
| NRS pain intensity(Participants) | High Dose APAP | Low Dose APAP | Placebo | Total |
|---|---|---|---|---|
| 0 = No pain | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 1 | 1 | 1 | 3 |
| 6 | 11 | 7 | 8 | 26 |
| 7 | 13 | 12 | 6 | 31 |
| 8 | 13 | 18 | 7 | 38 |
| 9 | 3 | 5 | 0 | 8 |
| 10 = Worst imaginable pain | 3 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Jul 2019, 3 months.
Results were first posted in Mar 2022, 2 years 8 months after primary completion.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Nevakar, Inc.